PursueCare to Spotlight Next-Gen Digital Therapeutics at the 56 th American Society of Addiction Medicine (ASAM) Conference in Denver April 24-27
With innovation at its core, PursueCare continues to lead the charge in transforming addiction care through accessible, scalable, and data-driven solutions.
Share
Honoring a Visionary in Addiction Medicine—Dr. Jason Kirby Named 2025 ASAM Distinguished Fellow
PursueCare's Medical Director, Dr. Jason Kirby, DO, MBA, DFASAM, has been named a 2025 Distinguished Fellow of ASAM, one of the society's highest honors. This prestigious designation recognizes Dr. Kirby's enduring commitment to evidence-based, outcomes-driven care and his leadership in improving access to treatment for individuals with substance use disorder (SUD).
'I began this journey nearly a decade ago with a mission to provide compassionate, science-backed care for people living with addiction. Being recognized as a Distinguished Fellow by ASAM is a profound honor,' said Dr. Kirby. 'It's a privilege to stand alongside so many esteemed leaders who are transforming the future of addiction medicine.'
With dual board certifications in addiction medicine and family medicine, and deep expertise in healthcare policy and population health, Dr. Kirby exemplifies the innovative and empathetic leadership PursueCare brings to the field.
Visit PursueCare at Booth #325—Experience RESET® and RESET-O®
Conference attendees are invited to Booth #325 to experience PursueCare's cutting-edge, virtual-first addiction treatment platform. The company will spotlight its latest advancements, including:
RESET® and RESET-O®—the first and only FDA-authorized digital therapeutics for SUD and opioid use disorder (OUD). Watch the video Transforming Addiction Treatment with RESET®.
Tools that offer 24/7 recovery support, blending cognitive behavioral therapy (CBT), contingency management, and real-time progress tracking within PursueCare's secure, proprietary smartphone applications.
These groundbreaking therapeutics are seamlessly embedded into PursueCare's care model, extending the reach and impact of virtual addiction care.
Elevating the Standards of Recovery
'Dr. Kirby's recognition as a Distinguished Fellow is a proud moment for everyone at PursueCare,' said Nick Mercadante, Founder and Chief Executive Officer. 'His tireless work to expand access and improve outcomes in virtual addiction treatment reflects our mission to reimagine what recovery looks like for people everywhere.' With innovation at its core, PursueCare continues to lead the charge in transforming addiction care through accessible, scalable, and data-driven solutions.
About PursueCare
PursueCare provides personalized virtual addiction treatment for individuals across states (CT, KY, MA, ME, NH, OH, and WV). Our mission is to increase access to chronic care through telehealth. Patients engage with a multi-disciplinary team providing medical care, counseling, psychiatry, and pharmacy. FDA-authorized digital cognitive behavioral therapy, RESET® and RESET-O®, supports recovery 24/7. We accept private insurance, Medicare, and Medicaid.
Learn more at www.pursuecare.com and www.reachforreset.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
7 hours ago
- Business Wire
Swisslog Healthcare Welcomes New Global Head of People & Organization
BROOMFIELD, Colo.--(BUSINESS WIRE)-- Swisslog Healthcare, a leading supplier in transport and pharmacy automation solutions, appoints Sarah Stary as the new Global Head of People & Organization. Stary brings over 18 years of global experience in human resources strategy, organizational development, and culture transformation to the role. In her new role, Stary will develop and execute people-centric strategies that support business growth, enhance organizational effectiveness, and drive a culture of engagement and inclusion. She will leverage her extensive experience in executive consulting, talent management, and leadership development to strengthen Swisslog Healthcare's workforce. "Swisslog Healthcare's mission to shape the future of healthcare automation aligns with my passion for developing high-performing teams," said Sarah Stary, Global Head of People & Organization at Swisslog Healthcare. "My focus will be on creating an environment where our talented workforce can innovate and deliver exceptional value to our customers and patients worldwide." 'I am excited to welcome Sarah on board. Her proven track record of building high-performing teams and cultures in global organizations combined with her strategic mindset, will be invaluable to our organization as we continue to grow and evolve. We look forward to her leadership in shaping our people strategy for the future,' said Cory Kwarta, CEO of Swisslog Healthcare. Prior to joining Swisslog Healthcare, Stary served as Human Resources Director EMEA at Trina Solar AG, where she led strategic HR initiatives across Europe, the Middle East, and Africa. She successfully managed mergers & acquisitions integrations, HR system implementations, and compliance management, aligning with global business objectives. Stary holds an Executive MBA from IE Business School, a Master's in Strategic HR Management from Bocconi University, and certifications in Coaching and Organizational Effectiveness from the University of Cambridge. Sarah is multi-lingual as she is fluent in German, English, and Spanish, and has intermediate skills in French, Mandarin, and some basic Italian. About Swisslog Healthcare: Swisslog Healthcare provides pharmacy workflow automations through robotic solutions and operational technology that enable hospitals and health systems to assist providers in treating patients across the continuum of care. Integrating transport and pharmacy automation, value-added services, and intelligent software, Swisslog Healthcare enables healthcare providers to respond to patients' needs quickly and with greater accuracy. The company minimizes many sources of operational waste, so providers achieve higher levels of productivity to impact the well-being of patients in positive ways. For more information, visit
Business Wire
9 hours ago
- Business Wire
Check City Honors Krrisha Patel With 2025 Richard Rawle Scholarship for Community-Driven Health Innovation
SALT LAKE CITY--(BUSINESS WIRE)--Check City, a nationwide financial services provider, is proud to announce Krrisha Patel as the 2025 recipient of the Richard Rawle Memorial Scholarship. This annual $2,000 scholarship honors students who demonstrate exceptional dedication to community service. Krrisha, an aspiring bioengineer, has spent the last several years addressing body image, healthcare inequality, mental health, and inclusive innovation in bioengineering and telehealth. Her journey began with Harvard's STRIPED Initiative, where she helped combat the dangers of diet pills and promote body positivity, contributing to legislation that prohibits their sale to minors. Motivated by peers facing eating disorders, she founded MetaHealth, a community group that offers nutrition workshops promoting healthy habits and self-image through inclusive dialogue and cuisine. At the Institute for Healing & Justice in Medicine, Krrisha researched how racial and gender identities influence medical diagnoses and treatments. She also supported public health initiatives in Nigeria, addressing diseases like typhoid fever, and interned at IPMD Inc., helping develop an emotional AI telemedicine platform. Now, she's exploring wearable sensors and inclusive design to expand equitable care access. The Richard Rawle Memorial Scholarship honors Check City's founder, whose life was defined by a commitment to lifting others. 'Krrisha embodies the spirit of this scholarship,' said the selection committee. 'Her community service efforts go beyond volunteerism—they reflect an ongoing, self-motivated commitment to making a broad impact on the world by lifting others and reshaping systems to be more inclusive and just.' As the 2025 recipient, Krrisha will receive scholarship funds for her academic journey. She plans to continue studying bioengineering and lead the next generation of health innovations, prioritizing diversity, equity, and upfront accessibility. The Rawle family and Check City firmly believe education plays a crucial role in community prosperity. This award gives deserving students the financial support to continue making a difference in their communities. Krrisha's work is a powerful reminder that service isn't just about giving back but moving forward together. About Check City Check City is a trusted financial services provider with locations across the United States. Founded on principles of community service and financial empowerment, Check City offers services like short-term lending, money transfers, and beyond. Learn more at
Business Wire
10 hours ago
- Business Wire
CorFlow Therapeutics宣布MOCA-II IDE關鍵性試驗獲得FDA核准，旨在驗證新型心臟病發作治療技術
瑞士巴爾--(BUSINESS WIRE)--(美國商業資訊)-- 專注於微血管疾病的心臟護理領域先驅企業 CorFlow Therapeutics AG (CorFlow) 今日宣布，該公司的技術已獲得美國食品藥物管理局(FDA)的研究性器材豁免(IDE)核准，這表示關鍵性臨床試驗可在美國各醫院啟動。CorFlow目前正準備為這些臨床試驗中心配備CorFlow系統，展開相關培訓，並開始招募接受心臟病治療的病患。 這項名為MOCA-II的IDE關鍵性試驗旨在前瞻性驗證專有CorFlow CoFl系統在原發性經皮冠狀動脈介入治療(PCI)過程中診斷微血管阻塞(MVO)存在與否的準確性。主要終點是將CoFI診斷結果與心臟磁振造影(MRI)掃描的診斷參考標準進行對比。該試驗已獲准在美國和歐洲的知名研究機構招募200多名ST段上升型心肌梗塞(STEMI)病患。 在2024年成功完成MOCA-I首次人體試驗後，MOCA-II研究成為將這一獨特技術推向全球介入心臟病學家的關鍵一步，協助其快速診斷心臟病發作病患的MVO問題。這進而可望為大量MVO病患帶來新的治療方法和護理路徑——目前這類病患的臨床不良結局發生率較高。CorFlow技術不僅旨在診斷MVO，還能做為局部藥物遞送系統，用於輸送診斷劑和治療劑，相關研究正在獨立進行中。 美國政府疾病控制與預防中心的資料顯示，美國每30秒就有一人突發心臟病，每年報告病例約80萬例。歐洲的發病率和患病率也處於類似高位。超過一半的STEMI心臟病發作病患被證實存在MVO，且既往研究顯示，MVO的存在是導致不良事件的主要因素。目前，在歐美地區，尚無獲准可在急性冠狀動脈介入治療期間診斷MVO的技術，也沒有專門針對MVO的獲准治療器材。心臟病發作及相關心臟疾病仍是全球導致死亡和身心障礙的主要原因之一。 CorFlow執行長Paul Mead表示：「介入心臟病學和心臟病發作護理領域的突破可追溯至100多年前，這是醫療護理進步的重大成功案例之一，但該領域的先驅和傑出人士都認同，這項工作尚未完成。大多數急性STEMI倖存者存在MVO問題，而目前這些病患的預後差得驚人。我們旨在揭露這一問題，並證明人們能夠為此採取行動。這一里程碑讓我們向兌現改善這些病患護理的承諾又邁進了一步——我們深知在這方面我們能做得更好。」 MOCA-II試驗由心臟病發作護理領域的世界知名專家主導，分別是美國俄亥俄州辛辛那提市基督醫院的Timothy Henry博士，以及瑞士盧加諾市提契諾心臟中心研究所的Marco Valgimigli教授。兩人在心血管研究領域共發表了超過1000篇經同儕審查的論文。 Tim Henry博士表示：「身為一名從事STEMI病患治療和研究數十年的介入心臟病學家，我對這項關鍵性試驗的啟動感到振奮不已——相關技術可望對病患的預後產生重大影響。我堅信，在原發性PCI過程中，在護理現場高度確信哪些病患存在MVO，能立即改變我們對病患的治療方式。」Valgimigli教授補充說道：「我是MOCA-I首次人體試驗的重要參與者，如今看到第二代技術可用於關鍵性試驗，我感到非常激動，並期待能進一步協助對MVO的即時科學理解。儘管醫學界對於如何治療這類病患存在不同觀點，但毫無疑問，準確診斷是我們需要邁出的第一步。我樂觀地認為，CorFlow技術獲准供同行介入心臟病學家日常使用後，將有助於推動該領域的發展。」 關於CorFlow Therapeutics：公司總部位於瑞士巴爾，在義大利和美國設有子公司。CorFlow由國際創投公司共同投資，最近一輪融資是2024年9月宣布的B輪融資。CorFlow立志成為診斷和治療解決方案領域的領導者，以恢復存在關鍵需求的人體任何部位的健康微血管血流。在瑞士創新署(Innosuisse)的資助下，CorFlow與伯恩大學、蘇黎世聯邦理工學院和蘇黎世大學醫院的科學家密切合作，持續探索這項獨特專利技術的應用場景。 免責聲明：本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用，煩請參照原文，原文版本乃唯一具法律效力之版本。
